Handelsbanken Fonder AB Sells 2,600 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Handelsbanken Fonder AB cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,277 shares of the biopharmaceutical company’s stock after selling 2,600 shares during the quarter. Handelsbanken Fonder AB’s holdings in Catalyst Pharmaceuticals were worth $425,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in shares of Catalyst Pharmaceuticals by 306.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 3,829 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $123,000. PNC Financial Services Group Inc. grew its position in shares of Catalyst Pharmaceuticals by 42.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 11,241 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 3,354 shares during the period. CenterBook Partners LP grew its position in shares of Catalyst Pharmaceuticals by 20.0% in the 3rd quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 2,259 shares during the period. Finally, Gallacher Capital Management LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $206,000. 79.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CPRX shares. HC Wainwright reiterated a “buy” rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Oppenheimer reiterated an “outperform” rating and issued a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $26.43.

Catalyst Pharmaceuticals Trading Up 1.0 %

NASDAQ CPRX opened at $15.20 on Thursday. The company has a market cap of $1.79 billion, a PE ratio of 24.92, a PEG ratio of 0.84 and a beta of 0.89. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.09 and a 12 month high of $17.76. The stock has a 50 day moving average of $15.62 and a 200-day moving average of $14.68.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.45 by $0.04. The company had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. As a group, sell-side analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current fiscal year.

Insider Activity

In other news, Director David S. Tierney sold 25,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.00% of the stock is currently owned by insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.